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ABSTRACT
Objectives: The industry perspective on drug costs should be framed by
the need for decision-makers to use actual and relevant costs, and to
inform real-world decisions regarding medication selection and use. The
objective of this report is to provide guidance and recommendations on
how manufacturers should approach the use of drug costs.
Methods: The Task Force was appointed with the advice and consent of
the ISPOR Board of Directors. Members were experienced developers or
users of drug cost information working in academia and industry, and
came from several countries. Following the core assumptions developed
and outlined by the Task Force, a draft report was prepared. Comments
were solicited on the outline and several draft reports both from a core
group of external reviewers and more broadly from the ISPOR member-
ship of ISPOR via the ISPOR Web site.
Results: The industry should always strive for: 1) a focus on drug value
and not just cost; 2) credibility—that is correct and consistent costs; 3)
transparency—by disclosing the prices and costs, and ensuring that they
reﬂect the actual cost of the drug whenever possible; and 4) providing
actionable results that help customers comprehend the value offered by a
drug therapy and to use products more efﬁciently and effectively.
Conclusions: Understanding and accounting for all costs and conse-
quences of the use of a medical treatment is in the best interests of all
parties involved in the prescribing, consuming, reimbursement, selling,
and manufacturing of bio/pharmaceuticals. Transparency, consistency,
and clear communication of costs and value are essential for appropriate
decision-making and should be important goals for all parties.
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Background to theTask Force
The ISPOR Task Force on Good Research Practices—Use of Drug
Costs for Cost Effectiveness Analysis (Drug Cost Task Force
[DCTF]) was recommended by the ISPOR Health Science Policy
Council onDecember 13, 2004 and approved by the ISPORBoard
of Directors on May 15, 2005. Because how drug costs should be
measured for cost-effectiveness analyses (CEAs) depend on the
perspectives, ﬁve Task Force subgroups were created to develop
drug costs standards from the societal, managed care, US govern-
ment, industry, and international perspective. This report is Part
V: an industry perspective (one of six reports from this ISPOR
Task Force on Good Research Practices—Use of Drug Costs for
Cost Effectiveness Analysis (DCTF). The other reports (Part I:
issues and recommendations; Part II: a societal perspective; Part
III: managed care; Part IV: US government perspective; and Part
VI: international perspective) are also published in this issue of
Value in Health (Volume 13, Issue 1). This DCTF subgroupmet to
develop core assumptions and an outline before preparing a draft
report. The Task Force subgroups held open forums and/or group
leader breakfast meetings at the ISPOR Annual International
Meetings and European Congresses. The draft report was circu-
lated to 174 Task Force primary reviewers (who were self-
identiﬁed from a broad range of perspectives). After this review, a
newdraft was prepared andmade accessible for broader review by
all ISPOR members. Comments for these reports by Task Force
primary reviewers and ISPOR membership are published at the
ISPOR website. All opinions reﬂect those of the authors and not
necessarily their afﬁliations.
Introduction
The objective of this report is to provide guidance and recom-
mendations on how manufacturers should approach the use of
drug costs. This task force report is part of a series of Good
Research Practices for estimating drug costs for pharmacoeco-
nomic and outcomes research studies. The reader is referred to
“Good Research Practices for Measuring Drug Costs in Cost
Effectiveness Analyses: Issues and Recommendations: A Report
of the ISPOR Drug Cost Task Force—Part I” for more details on
the Task Force, its goals, and objectives. This document reﬂects
the authors’ own experiences developing drug costs for use in
CEA models and publications but is not intended as a compre-
hensive review of the literature.
Task Force Process
The ISPOR Task Force on Good Research Practices—Use of
Drug Costs for Cost Effectiveness Analysis (DCTF) was
approved in 2005 by the ISPOR Board of Directors. The Chair of
the Industry Subgroup, Jack M. Mycka, was appointed by the
Task Force Chairs, Joel Hay and Jim Smeeding. All Subgroups
members were selected by the Subgroup Chairs from interested
ISPOR members.
The Task Force held teleconferences and used electronic mail
to develop core assumptions and an outline before preparing a
draft report. The Chair participated in face-to-face meetings held
at two ISPOR international meetings. Initial recommendations
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were presented at an open forum in May 2007. A draft report
was circulated among the Task Force leadership group for com-
ments. This draft report was then sent to the Drug Cost Stan-
dards Reviewer Group in August 2008 for a 1-month review
period and was made accessible for broader review by all ISPOR
members in October 2008. Several teleconferences of the Task
Force leadership group were held to discuss the comments
received and to incorporate feedback and make revisions. A ﬁnal
open forum was held in May 2009 to address comments received
on report drafts. This ﬁnal version reﬂects input from all of these
sources of comment.
Often, those examining the pharmaceutical and biotech
industry confuse the concepts of “value,” “price,” and “cost,”
using the terms interchangeably or assuming there is a direct
relationship among them. The price may or may not fully reﬂect
the economic value of the product or the actual cost of acquiring
and using it because, in general, medicines offer economic value
that is considerably higher than the prices that are charged for
them. Even within the industry, these terms are often confused
because of varying academic and practical views. In this article,
we will attempt to align the theoretical view of “where costs
should go” and the practical application of “making it happen.”
This alignment is essential as marketers build “value frames”
that can be used to discuss the merits of their products and to
support the drug selection and use decision-making process.
For purposes of clarity, we offer the following deﬁnitions:
• The price of a medicine is the monetary exchange compo-
nent of a business transaction.
• The cost of using a medicine includes the acquisition cost,
the costs of ancillary and associated products and proce-
dures, and the humanistic and societal costs that may be
incurred with the use of the medicine.
• The value of the medicine is the net of the clinical, eco-
nomic, and humanistic effects of the use of the medicine.
In different types of research, drug cost has different mean-
ings. For example, a budget impact analysis is obviously different
from a CEA, and they require different approaches to the con-
sideration of items like copayments. In CEAs, copays can be
ignored, but, depending on perspective, they may play an impor-
tant role in a budget impact analysis.
From an industry perspective, ensuring that cost goes beyond
acquisition cost to the drug’s value is what matters most. This
somewhat lofty goal needs to be balanced with the need to
provide relevant and clear information that can be used in
decision-making processes by manufacturers/marketers; payers;
physicians; patients; pharmacists; society in general; and all
others involved in prescribing, consuming, and paying for phar-
maceutical, biotech, and associated products.
Below we address both the theoretical goal and the short-
term practical goals that we believe the industry should pursue.
We have illustrated these statements with a few relevant
examples and recommendations.
Value versus Cost Focus
Studies should focus on the total value provided by the drug
(economic, humanistic, and operational value) and not just the
cost of the drug. Whether researchers look at the value of a
therapy or treatment regimen, the goal of a study that has a
meaningful impact on clinical decisions is more easily achievable.
The actions affected should be the clinical development and
pricing decisions of the manufacturer/marketer as well as those
of customers once a product is marketed after approval.
Total value. Discussions of value in health care are often limited
to narrow considerations of the direct costs of an intervention
and do not consider incorporating the broader aspects of value
listed below.
Economic value. The economic value of a treatment is the net
economic effect of its use, relative to alternative interventions,
considering all costs associated with the treatments and their
consequences. Although there are standard methods for the mea-
surement of economic value, often this measurement is limited to
price, drug acquisition cost, or some other narrow measure,
without consideration for broader economic effects.
Humanistic value. The humanistic value of a treatment is the net
effect of its use on the ability of a patient to perform and enjoy
the activities of daily living, relative to the effect of alternative
interventions. This type of value is commonly referred to as
“Quality of Life” and can be captured and reﬂected in a variety
of instruments. This value, however, can often be manifested in
individuals other than patients (e.g., caregivers, providers), and
these aspects of the humanistic value of a treatment must also be
considered.
Operational value. The operational value of a treatment is the
net effect on the physical aspects of providing care relative to
alternative interventions. Factors such as ease or difﬁculty of use,
administration, acquisition, compliance, and recognition of
effects have an impact on care that is seldom measured but must
be considered when the total value of a treatment is evaluated.
Attempts to quantify some of these factors have been made, and
their presence must be acknowledged in some manner, even
without quantiﬁcation.
A focus on total value often does not match the narrow
budget focus of decision-makers. This mismatch can be attrib-
uted to a difference between who bears the various cost compo-
nents and who enjoys the various value components. This is
apparent in different types of health economics studies. For
instance, with a budget impact model, all affected parties should
be considered, including patients, whose budget constraints
might affect actual utilization and other parties’ budgets through
mechanisms such as copayments. Similarly, various parties may
experience different aspects of the value of a drug in areas like
productivity gains and losses. This reality should be recognized
and acknowledged by making the differences apparent and as
easily separated as possible. Nevertheless, this does NOT relieve
all parties from the responsibility of examining the overall value
of medications in use and avoiding needless confusion related to
the cost (or other) data used.
Credibility
The use of prices should be both correct and consistent. Too
often, simple discrepancies in the price used (or not disclosed)
undermine the overall credibility of a study or model. We will
leave a discussion of the methodological differences among costs,
prices, and charges to a separate part of this effort. We believe,
however, that studies should not be conducted simply to support
a predetermined position; instead, studies should focus on the
relevance of the data presented to the customers likely to use it.
An example of the need for reality-based scenarios can be
seen in how a model’s assumptions need to change based upon its
time horizon. For instance, if a 25-year model is prepared, it
should reﬂect the expected market realities of price changes, if
any, during the patent-protected period and the impact of generic
entry and its related price erosion.
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Of course, this introduces additional variables such as the
amount of any price changes (increases and/or decreases), the
date that generics become available, and the prices of those
generics. From the opposite view, changes such as inﬂating prices
of competing products where there is no basis for the increase
should be avoided because they are methodologically inappro-
priate, obscure the usefulness of the model, and directly under-
mine its credibility.
Pricing Transparency
Because drug cost is almost always a key factor in these studies,
the prices used should be disclosed and should reﬂect the actual
cost of the drug whenever possible. To achieve a true compari-
son, drug prices used in studies must reﬂect different dosing
regimens and use patterns in the real world rather than simply
relying on the respective product package inserts. This same
principle applies across countries and payment systems, and the
basis for these key factors should always be disclosed. A practical
and reasonable ﬁrst step would be to ensure that an explicit
statement deﬁning the perspective and scope of the costs cited is
included. This will enable users to easily identify the basis used
and to assess the comparability and adaptability of the informa-
tion to their own situation.
An example in this area is the inclusion (or exclusion) of value
added tax (VAT) in European drug price analyses. VAT could
have a signiﬁcant impact on the results and their comparability,
especially when it is very high (~23%) and the comparator is
placebo or conservative care, where prices, let alone VAT, may
not exist. This same issue needs to be accounted for if these
studies are conducted and/or applied outside of the EU where tax
systems (as well as distributions and pharmacy margins) can be
signiﬁcantly different.
A US-based example in this area is the evolution from average
wholesale price toward wholesale acquisition cost or ex-factory
price and beyond to average sales price (ASP) and average manu-
facturer price. For instance, although ASP is an average, it more
accurately reﬂects actual costs after discounts and rebates, and it
is readily and consistently available for many drugs. Using the
same price level across products and disclosing which price level
is used is a simple ﬁrst step toward transparency.
Transparency as to the price used and its relevance to par-
ticular payers (government, commercial, patients, etc.) is critical
to meaningful evaluation. The drug costs used should reﬂect
actual amounts wherever possible, and care must be taken to
disclose the costs used so that comparisons can be made. Accu-
rate comparison becomes especially difﬁcult when costs are
examined on a multinational basis where prices are different and
reﬂect the impact of different payment systems and economic
realities, such as various margin and VAT differences.
Actionable Results
By focusing on value and ensuring the credibility and transpar-
ency of costs used, researchers will ensure that the results of
studies and models will be more valuable to all decision-makers
(including the manufacturer/marketer). The results from such
studies will help customers to comprehend the value offered by a
drug therapy and to use products more efﬁciently and effectively.
This goal of actionable results should be achievable. Opti-
mally, pricing, research, and modeling will all support decision-
making outside of siloed perspectives while also recognizing their
existence. Meaningful and transparent data will promote clear
communication and keep all decision-makers from hiding inside
their respective silos.
Understanding and accounting for all costs and consequences
of the use of a medical treatment is in the best interests of all
parties involved in the prescribing, consuming, reimbursement,
selling, and manufacturing of bio/pharmaceuticals. This concept
is especially important because the use of models and other
decision support mechanisms is growing in acceptance, and these
models must be fully populated. Transparency, consistency, and
clear communication of costs and value are essential for appro-
priate decision making and should be important goals for all
parties.
Source of ﬁnancial support: None.
Industry Perspective on Drug Costs 27
